Division of Nephrology, Department of Medicine, San Francisco VA Medical Center, San Francisco, CA; Kidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, CA.
Kidney Research Institute, University of Washington, Seattle, WA.
Am J Kidney Dis. 2018 Aug;72(2):205-213. doi: 10.1053/j.ajkd.2017.12.013. Epub 2018 Mar 27.
RATIONALE & OBJECTIVE: Novel urinary biomarkers have enabled earlier detection of kidney tubular damage, but their prognostic value for adverse cardiovascular outcomes is uncertain. We hypothesized that tubular damage, measured by urine α-microglobulin (A1M), amino-terminal propeptide of type III procollagen (PIIINP), and neutrophil gelatinase-associated lipocalin (NGAL), would be associated with higher risks for cardiovascular events and mortality among elders.
Case-cohort study.
SETTING & PARTICIPANTS: This study included a randomly selected subcohort (n=502), cardiovascular disease (CVD) cases (n=245), and heart failure cases (n=220) from the Health, Aging, and Body Composition (Health ABC) Study.
Baseline urine A1M, PIIINP, and NGAL concentrations.
Incident CVD, heart failure, and all-cause mortality.
Cox proportional hazards models were used to evaluate biomarker associations with each outcome.
At baseline, mean age was 74 years and estimated glomerular filtration rate was 73mL/min/1.73m. After adjustment for demographics, estimated glomerular filtration rate, albumin-creatinine ratio, and other cardiovascular risk factors, each doubling in biomarker concentration was associated with the following adjusted HRs for CVD: A1M, 1.51 (95% CI, 1.16-1.96); PIIINP, 1.21 (95% CI, 1.00-1.46); and NGAL, 1.12 (95% CI, 1.05-1.20). There were 248 deaths in the subcohort during a median follow-up of 12.4 years. Adjusted associations of each biomarker (HR per doubling) with all-cause mortality were: A1M, 1.29 (95% CI, 1.10-1.51); PIIINP, 1.05 (95%, 0.94-1.18); and NGAL, 1.07 (95% CI, 1.02-1.12). Biomarker concentrations did not have statistically significant associations with heart failure after multivariable adjustment.
Urine biomarkers were measured at a single time point; no validation cohort available.
Kidney tubular damage is an independent risk factor for CVD and death among elders. Future studies should investigate mechanisms by which kidney tubular damage may adversely affect cardiovascular risk.
新型尿生物标志物可更早地检测到肾小管损伤,但它们对不良心血管结局的预后价值尚不确定。我们假设,通过尿液α-微球蛋白(A1M)、III 型前胶原氨基端前肽(PIIINP)和中性粒细胞明胶酶相关脂质运载蛋白(NGAL)测量的肾小管损伤与老年人心血管事件和死亡率的风险增加相关。
病例-队列研究。
本研究包括来自健康、衰老和身体成分研究(Health ABC)的一个随机选择的子队列(n=502)、心血管疾病(CVD)病例(n=245)和心力衰竭病例(n=220)。
基线尿 A1M、PIIINP 和 NGAL 浓度。
在基线时,平均年龄为 74 岁,估算肾小球滤过率为 73mL/min/1.73m。在调整了人口统计学、估算肾小球滤过率、白蛋白-肌酐比值和其他心血管危险因素后,每种生物标志物浓度的翻倍与以下调整后的 CVD 风险比相关:A1M,1.51(95%置信区间,1.16-1.96);PIIINP,1.21(95%置信区间,1.00-1.46);NGAL,1.12(95%置信区间,1.05-1.20)。在中位数为 12.4 年的随访中,子队列中有 248 人死亡。与每种生物标志物(每翻倍的 HR)相关的全因死亡率的调整后关联为:A1M,1.29(95%置信区间,1.10-1.51);PIIINP,1.05(95%置信区间,0.94-1.18);NGAL,1.07(95%置信区间,1.02-1.12)。在多变量调整后,生物标志物浓度与心力衰竭无统计学显著关联。
尿生物标志物仅在一个时间点测量;没有可用的验证队列。
肾小管损伤是老年人 CVD 和死亡的独立危险因素。未来的研究应探讨肾小管损伤可能如何对心血管风险产生不利影响的机制。